Biocon Biologics refinances USD 1.1 billion long term debt through USD Bonds new syndicated facility Ruchika Sharma5 Oct 2024 11:30 AM ISTBengaluru: Biocon Biologics Limited, a subsidiary of Biocon Limited, has announced the successful pricing of Biocon Biologics' debut USD 800 million...
USFDA concludes inspection at Biocon Biologics Malaysia Insulins facility Ruchika Sharma30 Sept 2024 1:15 PM ISTKarnataka: Biocon Biologics has announced that the US Food and Drug Administration (USFDA) has completed a cGMP inspection at the Company's...
Biocon Biologics announces New Dermatology data to be presented at EADV Congress 2024 Ruchika Sharma25 Sept 2024 2:48 PM ISTBengaluru: Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd has announced new dermatology data presented at the European Academy of...
Biocon Biologics secures market entry for Bmab 1200 in Europe, UK, Canada, Japan Ruchika Sharma29 Aug 2024 12:30 PM ISTBangalore: Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and a subsidiary of Biocon Ltd, announced today that the...
Biocon Biologics plans to raise Rs 4,000-4,500 crore via local bonds: Report Ruchika Sharma8 July 2024 12:30 PM ISTBiocon Biologics Ltd., a biopharmaceutical company, is considering raising between Rs 4,000 crore and Rs 4,500 crore from India’s local-currency bond...
Biocon arm receives EMA approval to manufacture biosimilar Bevacizumab at Bengaluru facility Ruchika Sharma24 Jun 2024 12:15 PM ISTBengaluru: Biocon Biologics Ltd, a global, fully integrated biosimilars company and a subsidiary of Biocon Ltd, has received approval from the...
Biocon Biologics forays into US Ophthalmology market with USFDA nod for Yesafili Ruchika Sharma21 May 2024 11:30 AM ISTBengaluru: Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd, today announced that the U.S....
Eris Lifesciences acquires Biocon Biologics India branded formulation business for Rs 1242 crore Susmita Roy15 March 2024 1:51 PM ISTMumbai: Eris Lifesciences Ltd., a branded formulations company, has announced the acquisition of Biocon Biologics' India branded formulation...
Biocon Biologics secures US market entry date for Bmab 1200, a Proposed Biosimilar to Stelara Ruchika Sharma1 March 2024 3:30 PM ISTStelara (Ustekinumab) is a monoclonal antibody medication that prevents abnormal regulation of interleukin IL-12/23 associated immune diseases and has...
Biocon Biologics Biocon Campus (Site 1) facility gets 4 USFDA observations Ruchika Sharma1 March 2024 12:01 PM ISTBangalore: Biocon has recently announced that the U.S. Food and Drug Administration (USFDA) has issued Form 483s with 4 observations at...
Biocon Biologics, Sandoz Australia ink pact for biosimilars Trastuzumab, Bevacizumab Ruchika Sharma9 Feb 2024 12:30 PM ISTTrastuzumab is a biosimilar of Herceptin and Bevacizumab is a biosimilar of Avastin - both biosimilars are available on the PBS and utilised for the...
Biocon Biologics, Sandoz ink pact for distribution of immune disorder injection Adalimumab in Japan Ruchika Sharma23 Dec 2023 12:30 PM ISTAdalimumab BS for subcutaneous injection [FKB] is a biosimilar of Humira (generic name: adalimumab (genetical recombination)) and is indicated for...
